Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New poster on liver inflammation at Endo

<< Previous

Bullboard Posts

Next >>

Comment by ANALIAS00on Mar 21, 2021 11:01am

122 Views

Post# 32846745

RE:New poster on liver inflammation at Endo

Light question ...

Who knew about the "Endocrine Societys annual meeting, ENDO 2021" ?

Why important enought to send a PR after that meeting and not enought to send a PR announcing that they would be attending that meeting ?

Is it just normal in the industry or part of a strategy ?

jfm1330 wrote: Strange to publish that on a friday night.

https://www.abstractsonline.com/pp8/#!/9188/presentation/2240

https://www.theratech.com/theratechnologies-announces-new-data-demonstrating-tesamorelins-positive-effect-on-immune-response-linked-to-liver-inflammation/